Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study’s senior authors. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were “reeducated” to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.
A History of Scientific Achievements for Cell-Based Therapies
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body’s own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body’s own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.
“Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients,” said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study’s senior authors. “It’s extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up.”
In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.
Results Demonstrate Potential of New Therapy
In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation — the standard of care and the only curative option for B-ALL patients — following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.
The Latest on: Cell therapy
[google_news title=”” keyword=”Cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cell therapy
- FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversighton May 9, 2024 at 8:33 am
ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene therapies, especially for rare diseases.
- Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Findson May 9, 2024 at 6:34 am
An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve β-cell function.
- As Ozzy Osbourne announces stem cell therapy, experts urge caution, highlight riskson May 9, 2024 at 2:00 am
As rock legend Ozzy Osbourne has turned to stem cell therapy, some experts caution that the treatment is not for everyone. A doctor weighed in on the potential risks.
- Regeneron's cell medicines chief is crafting a new cell therapy 'secret sauce'on May 9, 2024 at 2:00 am
Phil Gregory’s new gig looks a whole lot like his old gig. It’s just that, under the umbrella of Regeneron, things have gotten a bit bigger. | Phil Gregory’s new gig looks a whole lot like his old gig ...
- Revolutionary CAR-T cell therapy looks to break through beyond blood canceron May 8, 2024 at 1:00 pm
In just a decade, a new treatment has revolutionized the prognosis for people diagnosed with blood cancer. It’s called CAR-T cell therapy, a stunning achievement of genetic engineering that consists ...
- Vertical Bioreactors Could Benefit Cell Therapy Sectoron May 8, 2024 at 1:00 pm
A number of methods will be used for cell therapies, especially in cell expansion. Autologous and allogeneic therapies have different needs.
- Cell therapy fails to slow early type 1 diabetes, but safety is establishedon May 8, 2024 at 11:00 am
Despite the negative finding, researchers said there is still promise in the strategy of amplifying and infusing the immune cells of newly diagnosed type 1 diabetes patients.
- Stem Cell Therapy Improves Post-Stroke Motor Functionon May 7, 2024 at 5:00 pm
The open-label, dose-escalation treatment (2.5, 5, 10, and 20 million cells) included tacrolimus immunosuppression for 8 weeks. Physical therapy was encouraged but not required. The final patient will ...
- High costs, investor exit prompt closure of cell therapy biotech Walking Fishon May 7, 2024 at 10:30 am
Now, he’s helming a new venture, Ten30 Bio, which is working on oral molecules. Reflecting on Walking Fish’s work, Williams concedes that the cost of cell therapy manufacturing and associated clinical ...
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefitson May 3, 2024 at 5:08 am
Fox 17 provides local news, weather, sports, traffic and entertainment for Nashville and nearby towns and communities in Middle Tennessee, including Forest Hills, Brentwood, Franklin, Fairview, ...
via Bing News